Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy

Por Kevin McLaughlin PharmD, BCPS, Jessica Rimsans PharmD, BCPS, Katelyn W. Sylvester PharmD, BCPS, CACP, John Fanikos Rph, MBA, David M. Dorfman MD, PhD, Patricia Senna MT, ASCP, Jean M. Connors MD, Samuel Z. Goldhaber MD
Publicado em 2019-09-01